Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibiotic eye drops aim to cure pink eye faster

NCT ID NCT06911424

Disease control Sponsor: Baxis Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether fusidic acid 1% eye drops can cure bacterial conjunctivitis (pink eye) better than a placebo. About 400 adults and children with confirmed bacterial infection will receive either the antibiotic or placebo drops for a short time. The study measures how many people are cured and if the bacteria are cleared from the eye.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fusidic acid 1% eye drops
What this could lead to
If successful, this could provide a proven antibiotic eye drop option for treating bacterial conjunctivitis, potentially reducing symptoms faster than no treatment.
What could go wrong
This is a late-stage trial, but the effect must beat a placebo. Bacterial conjunctivitis often clears on its own, so the benefit may be modest. Side effects from eye drops are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: * Have a clinical diagnosis of suspected bacterial conjunctivitis in at least 1 eye, confirmed by the presence of purulent or mucopurulent ocular discharge and a grade ≥ 1 on the modified Validated Bulbar Redness (VBR) conjunctival redness scale. * Have not received any ocular treatment for conjunctivitis, aside from eyelid hygiene, ≤14 days prior to Visit 1. * Have a negative viral conjunctivitis test in both eyes. * Agree to discontinue use of eye/eyelid cosmetics during study participation. * Agree to discontinue use of contact lenses during study participation. * Be willing and able to provide informed consent and comply with the study requirements. * Not be currently pregnant or breastfeeding. If sexually active, agree to use approved contraception for the duration of the study. Main Exclusion Criteria: * Have signs and/or symptoms or a diagnosis of fungal, protozoal, or viral etiology ≤30 days prior to Visit 1. * Have experienced signs and symptoms of bacterial conjunctivitis for \>48 hours prior to Visit 1. * Require or are expected to require use of any non-study topical ocular medication or systemic medications prior to Visit 1 as specified in the protocol as ineligible. * Have any abnormality of the ocular anatomy or ocular disease/disorder specified in the protocol as ineligible. * Have a known intolerance, sensitivity or allergy to the study medications or any of their components. * Have participated in another clinical trial ≤30 days or received another experimental drug ≤90 days prior to Visit 1. * Have a family member or household member enrolled in this study. * Have a condition which in the investigator's opinion may impact their safety or would negatively affect the conduct or outcome of the study. * Be an employee of or immediate family member of an employee (directly related to study conduct) at the study site.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial conjunctivitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial conjunctivitis bacterial infectious disease Conjunctival Diseases conjunctivitis eye disorder Eye Infections, Bacterial eye infectious disorder Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacterial conjunctivitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    21 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Baxis Site 01

    RECRUITING

    Miami, Florida, 33155, United States

    Contact Email: •••••@•••••

  • Baxis Site 02

    TERMINATED

    Humble, Texas, 77338, United States

  • Baxis Site 03

    TERMINATED

    Miami, Florida, 33176, United States

  • Baxis Site 04

    RECRUITING

    Little Rock, Arkansas, 72205, United States

    Contact Email: •••••@•••••

  • Baxis Site 05

    TERMINATED

    Mount Airy, North Carolina, 27030, United States

  • Baxis Site 06

    RECRUITING

    Orland Park, Illinois, 60462, United States

    Contact Email: •••••@•••••

  • Baxis Site 08

    RECRUITING

    Edinburg, Texas, 78539, United States

    Contact Email: •••••@•••••

  • Baxis Site 09

    WITHDRAWN

    Pittsburgh, Pennsylvania, 15227, United States

  • Baxis Site 10

    RECRUITING

    Tampa, Florida, 33613, United States

    Contact Email: •••••@•••••

  • Baxis Site 11

    RECRUITING

    Lake Worth, Florida, 33460, United States

    Contact Email: •••••@•••••

  • Baxis Site 12

    RECRUITING

    Charleston, South Carolina, 29414, United States

    Contact Email: •••••@•••••

  • Baxis Site 13

    TERMINATED

    Miami Beach, Florida, 33140, United States

  • Baxis Site 14

    TERMINATED

    Kingwood, Texas, 77345, United States

  • Baxis Site 15

    TERMINATED

    Idaho Falls, Idaho, 83404, United States

  • Baxis Site 16

    WITHDRAWN

    West Valley City, Utah, 84120, United States

  • Baxis Site 17

    TERMINATED

    Layton, Utah, 84041, United States

  • Baxis Site 18

    TERMINATED

    Layton, Utah, 84041, United States

  • Baxis Site 19

    RECRUITING

    La Jolla, California, 92037, United States

    Contact Email: •••••@•••••

  • Baxis Site 20

    TERMINATED

    Sherman Oaks, California, 91423, United States

  • Baxis Site 21

    TERMINATED

    North Las Vegas, Nevada, 89030, United States

  • Baxis Site 22

    TERMINATED

    Doral, Florida, 33172, United States

  • Baxis Site 23

    WITHDRAWN

    Babylon, New York, 11702, United States

  • Baxis Site 24

    WITHDRAWN

    Huntington Beach, California, 92647, United States

  • Baxis Site 25

    WITHDRAWN

    Tulsa, Oklahoma, 74133, United States

  • Baxis Site 26

    WITHDRAWN

    Columbia, Maryland, 21045, United States

  • Baxis Site 27

    RECRUITING

    Lutz, Florida, 33549, United States

    Contact Email: •••••@•••••

  • Baxis Site 28

    RECRUITING

    Miami Lakes, Florida, 33014, United States

    Contact Email: •••••@•••••

  • Baxis Site 29

    RECRUITING

    Palm Springs, Florida, 33461, United States

    Contact Email: •••••@•••••

  • Baxis Site 30

    RECRUITING

    Gresham, Oregon, 97030, United States

    Contact Email: •••••@•••••

  • Baxis Site 31

    RECRUITING

    Los Angeles, California, 90020, United States

    Contact Email: •••••@•••••

  • Baxis Site 32

    RECRUITING

    Charlottesville, Virginia, 22902, United States

    Contact Email: •••••@•••••

  • Baxis Site 33

    RECRUITING

    Greenville, South Carolina, 29607, United States

    Contact Email: •••••@•••••

  • Baxis Site 34

    RECRUITING

    Delray Beach, Florida, 33484, United States

    Contact Email: •••••@•••••

  • Baxis Site 35

    RECRUITING

    Union City, Georgia, 30291, United States

    Contact Email: •••••@•••••

  • Baxis Site 36

    RECRUITING

    Mission, Texas, 78572, United States

    Contact Email: •••••@•••••

  • Baxis Site 37

    RECRUITING

    Largo, Florida, 33773, United States

    Contact Email: •••••@•••••

  • Baxis Site 38

    RECRUITING

    Los Angeles, California, 90048, United States

    Contact Email: •••••@•••••

  • Baxis Site 39

    RECRUITING

    Long Beach, California, 90813, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.